Compare AIMD & QNME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AIMD | QNME |
|---|---|---|
| Founded | 1984 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Integrated Freight & Logistics |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.6M | 10.5M |
| IPO Year | 2008 | 2024 |
| Metric | AIMD | QNME |
|---|---|---|
| Price | $1.24 | $0.24 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 4.0M | 573.1K |
| Earning Date | 11-16-2026 | 11-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 47.83 |
| EPS | N/A | ★ N/A |
| Revenue | $124,157.00 | ★ $5,850,681.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 498.95 | 111.79 |
| 52 Week Low | $0.43 | $0.24 |
| 52 Week High | $3.88 | $1.40 |
| Indicator | AIMD | QNME |
|---|---|---|
| Relative Strength Index (RSI) | 60.79 | 33.15 |
| Support Level | $0.50 | N/A |
| Resistance Level | $1.75 | $0.43 |
| Average True Range (ATR) | 0.30 | 0.04 |
| MACD | 0.08 | -0.01 |
| Stochastic Oscillator | 51.47 | 2.36 |
Ainos Inc is a dual-platform company advancing artificial intelligence based smelltech technologies and immune therapeutics. Its primary strategic focus is the commercialization of its proprietary scent digitization platform, AI Nose, while the company also continue to develop therapeutic assets based on its low-dose oral interferon program, VELDONA. Its core technology platform, AI Nose, is an AI-based electronic olfaction system that integrates gas sensor arrays with proprietary artificial intelligence models, which it refers to as a smell language model (SLM), to digitize scent and volatile organic compound (VOC) signals into Smell ID, a machine-readable data format.
Quanome Technologies Inc operates in the midstream segment of the pharmaceutical industrial ecosystem, operating between upstream pharmaceutical manufacturers and downstream medical end customers. It sources products from multiple manufacturers and suppliers, and distribute them to hospitals, pharmaceutical distributors and other healthcare providers. Its principal product categories include infusion products, foods for special medical purposes, and specialty pharmaceuticals. It operates in one reportable segment serves its customers by providing pharmaceutical products in China. The company generates a substantial percentage of its revenue from selling pharmaceutical products on a direct basis.